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ABSTRACT
Purpose: REACH investigated second-line ramucirumab therapy for advanced 
hepatocellular carcinoma. 
Results: Median overall survival was 8.2 months for ramucirumab and 6.9 months for 
placebo (HR, 0.835; 95% CI, 0.634–1.100; p = 0.2046) for East Asians, and 10.1 months 
for ramucirumab and 8.0 months for placebo (HR, 0.895; 95% CI, 0.690–1.161;  
p = 0.4023) for non-East Asians. Median overall survival in patients with baseline 
alpha-fetoprotein ≥ 400 ng/mL was 7.8 months for ramucirumab and 4.2 months for 
placebo (HR, 0.749; 95% CI, 0.519–1.082; p = 0.1213) for East Asians (n = 139), 
and 8.2 months for ramucirumab and 4.5 months for placebo (HR, 0.579; 95% CI, 
0.371–0.904; p = 0.0149) for non-East Asians (n = 111). The most common grade 
≥ 3 treatment-emergent adverse events in East Asians and non-East Asians included 
hypertension and malignant neoplasm progression. 
Materials and methods: A post-hoc analysis of East Asians (N = 252) and non-
East Asians (N = 313) in the intent-to-treat population was performed. 
Conclusions: In East Asians and non-East Asians, ramucirumab did not 
significantly prolong overall survival. In patients with baseline alpha-fetoprotein 
≥ 400 ng/mL, a potentially larger survival benefit was observed in both subgroups. 
Safety for East Asians was similar to non-East Asians.
INTRODUCTION
Among cancer deaths, liver cancer is the second 
most common cause [1]. Hepatocellular carcinoma 
represents approximately 70% to 90% of primary liver 
cancers [1, 2]. The incidence rates of liver cancer are 
highest in East Asian (EA) countries [1]. Intermediate 
rates occur in Southern Europe and Northern America, and 
the lowest rates occur in Northern Europe [1]. In general, 
EA patients have a poorer prognosis than non-EA patients. 
In the Asia-Pacific study of sorafenib versus placebo in EA 
patients, median overall survival (OS) in both treatment 
arms was shorter than the median OS in either arm of 
the SHARP study of sorafenib versus placebo in a global 
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cohort of patients [3, 4]. Nonetheless, the relative hazard 
ratios for survival benefits were similar [3, 4]. Survival 
was also shorter for EA patients compared to non-EA 
patients in the GIDEON non-interventional study [5]. The 
reasons for the shorter survivals in EA patients remain 
unclear, but may include differences in tumor-related 
factors or patient characteristics. The most common cause 
of liver cancer in EA patients is hepatitis B virus infection, 
which is prevalent in this region, whereas hepatitis C virus 
or alcohol use are the most common causes of liver cancer 
in non-EA patients [6]. Disease management can also 
vary across regions [7], and EA patients are more likely 
to present at a more advanced stage of the disease [8, 9]. 
Vascular endothelial growth factor (VEGF) and 
VEGF receptor-2 (VEGFR-2)-mediated signaling are 
important in the proliferation of hepatocellular carcinoma 
tumors [10–13]. Ramucirumab, a recombinant human 
IgG1 monoclonal antibody, binds with high affinity and 
specificity to the extracellular domain of VEGFR-2, 
preventing angiogenesis via VEGF- and VEGFR-2-
mediated signaling [14]. Ramucirumab in patients with 
advanced hepatocellular carcinoma as a second-line 
treatment following first-line therapy with sorafenib did 
not demonstrate a significant OS improvement over best 
supportive care (primary endpoint) in the phase III REACH 
trial [15]. However, improvements in progression-free 
survival (PFS) and response rate were observed [15]. In a 
pre-specified subgroup analysis of patients with a baseline 
alpha-fetoprotein (AFP) ≥ 400 ng/mL, ramucirumab 
treated patients had improved OS compared to placebo-
treated patients [15].
A post-hoc subgroup analysis of the REACH trial 
was performed in advanced hepatocellular carcinoma 
EA and non-EA patients following first-line therapy with 
sorafenib to explore safety and efficacy of ramucirumab 
treatment in these patient populations.
RESULTS
Patients
Figure 1 shows the CONSORT diagram for EA 
and non-EA patients. A total of 252 EA patients were 
randomized to receive ramucirumab (N = 126) or placebo 
(N = 126); 313 non-EA patients were randomized to 
receive ramucirumab (N = 157) or placebo (N = 156).
Baseline patient and disease characteristics for 
EA and non-EA patients were generally well balanced 
between treatment arms (Table 1). Differences between 
EA and non-EA patients were observed for age, Eastern 
Cooperative Oncology Group performance status (ECOG 
PS), etiology of liver disease, primary tumor present, 
presence of extra-hepatic spread, Barcelona Clinic Liver 
Cancer stage, baseline AFP, prior systemic therapy, and 
reasons for discontinuation of prior sorafenib therapy. 
Most differences were consistent with EA patients having 
a worse prognosis compared to non-EA patients.
Efficacy 
In EA patients, median OS for ramucirumab-
treated patients was 8.2 months and 6.9 months for 
placebo-treated patients (stratified HR, 0.835; 95% CI, 
0.634–1.100; p = 0.2046) (Figure 2). Median PFS was 2.2 
months for the ramucirumab arm and 1.5 months for the 
placebo arm (stratified HR, 0.721; 95% CI, 0.555–0.937; 
p = 0.0141) (Figure 2). The objective response rate (ORR) 
was 5.6% (95% CI, 2.7–11.0) for the ramucirumab arm 
and 0.8% (95% CI, 0.1–4.4) for placebo arm (p = 0.0298) 
(Table 2). The disease control rate (DCR) was 47.6% for 
the ramucirumab arm and 42.1% for the placebo arm 
(p = 0.3568). 
In non-EA patients, median OS for ramucirumab-
treated patients was 10.1 months and 8.0 months for 
placebo-treated patients (stratified HR, 0.895; 95% CI, 
0.690–1.161; p = 0.4023) (Figure 2). Median PFS was 
4.5 months for the ramucirumab arm and 2.7 months for the 
placebo arm (stratified HR, 0.549; 95% CI, 0.427–0.706; 
p < 0.0001) (Figure 2). The ORR was 8.3% (95% CI, 
4.9–13.7) for the ramucirumab arm and 0.6% (95% CI, 
0.1–3.5) for the placebo arm (p = 0.0012) (Table 2). The 
DCR was 63.1% for the ramucirumab arm and 48.7% for 
the placebo arm (p = 0.0096) (Table 2). 
In EA patients with AFP ≥400 ng/mL (n = 139), 
median OS for the ramucirumab arm (n = 66) was 
7.8 months and 4.2 months for the placebo arm (n = 73) 
(HR, 0.749; 95% CI, 0.519–1.082; p = 0.1213) (Figure 3). 
In non-EA patients with AFP ≥ 400 ng/mL (n = 111), 
median OS for ramucirumab-treated patients was 
8.2 months (n = 53) and 4.5 months for placebo-
treated patients (n = 58) (stratified HR, 0.579; 95% CI, 
0.371–0.904; p = 0.0149) (Figure 3). 
In EA patients with AFP < 400 ng/mL (n = 113), 
median OS for the ramucirumab arm (n = 60) was 9.0 
months and 12.4 months for the placebo arm (n = 53) 
(HR, 1.083; 95% CI, 0.701–1.672; p = 0.7091) (Figure 3). 
In non-EA patients with AFP < 400 ng/mL (n = 197), 
median OS for ramucirumab–treated patients was 
11.4 months (n = 100) and 11.6 months for placebo-
treated patients (n = 97) (stratified HR, 1.099; 95% CI, 
0.783–1.543; p = 0.5804) (Figure 3).
Post-discontinuation systemic anti-cancer therapies 
(PDT) were similar for ramucirumab and placebo-treated 
patients in both EA and non-EA subgroups; however, a 
higher percentage of EA patients received PDT than 
non-EA patients (EA: 37.3% for the ramucirumab arm 
vs. 38.1% for the placebo arm; non-EA: 20.4% for the 
ramucirumab arm vs. 26.9% for the placebo arm). 
Safety
The EA safety population consisted of 123 patients 
in the ramucirumab arm and 123 patients in the placebo 
arm. The non-EA safety population consisted of 154 
patients in the ramucirumab arm and 153 patients in the 
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placebo arm. The incidences of grade ≥ 3 treatment-
emergent adverse events (TEAEs) were higher in the 
ramucirumab arm than the placebo arm for EA and 
non-EA patients (Tables 3 and 4). Any grade TEAEs 
occurring in at least 15% of patients and at a higher 
rate (at least 10% difference) in the ramucirumab arm 
than the placebo arm were peripheral edema, diarrhea, 
headache, thrombocytopenia, proteinuria, hypertension, 
hypoalbuminemia, and epistaxis for EA patients (Table 3), 
and peripheral edema, ascites, asthenia, hypertension, 
headache, and thrombocytopenia for non-EA patients 
(Table 4). Grade ≥ 3 TEAEs that occurred in at least 5% 
Table 1: Baseline characteristics










Median (range) 61 (34–85) 59 (25–83) 66 (28–87) 64 (30–85)
< 65 80 (63.5) 83 (65.9) 70 (44.6) 79 (50.6)
≥ 65 46 (36.5) 43 (34.1) 87 (55.4) 77 (49.4)
Male 107 (84.9) 112 (88.9) 129 (82.2) 130 (83.3)
ECOG PSa
0 63 (50.0) 63 (50.0) 96 (61.1) 90 (57.7)
1 63 (50.0) 63 (50.0) 61 (38.9) 66 (42.3)
Etiology of liver disease
Hepatitis B 79 (62.7) 76 (60.3) 30 (19.1) 31 (19.9)
Hepatitis C 31 (24.6) 28 (22.2) 52 (33.1) 49 (31.4)
Significant alcohol use 10 (7.9) 13 (10.3) 49 (31.2) 50 (32.1)
Steatohepatitis (fatty liver) 3 (2.4) 4 (3.2) 16 (10.2) 16 (10.3)
Other 3 (2.4) 3 (2.4) 3 (1.9) 7 (4.5)
Unknown 10 (7.9) 8 (6.3) 30 (19.1) 26 (16.7)
Baseline Child-Pugh Class A 125 (99.2) 125 (99.2) 152 (96.8) 151 (96.8)
Primary tumor present 107 (84.9) 106 (84.1) 150 (95.5) 146 (93.6)
Macrovascular invasion present 40 (31.7) 37 (29.4) 42 (26.8) 42 (26.9)
Extrahepatic spread present 98 (77.8) 102 (81.0) 109 (69.4) 98 (62.8)
Baseline BCLC Stage
Stage B 10 (7.9) 13 (10.3) 23 (14.6) 21 (13.5)
Stage C 116 (92.1) 113 (89.7) 134 (85.4) 135 (86.5)
Prior sorafenib therapy
Sorafenib only 99 (78.6) 102 (81.0) 145 (92.4) 151 (96.8)
Sorafenib and other systemic therapy 27 (21.4) 24 (19.0) 12 (7.6) 5 (3.2)
Reason for discontinuation of sorafenib
Progressive disease 116 (92.1) 112 (88.9) 130 (82.8) 127 (81.4)
Toxicity 10 (7.9) 14 (11.1) 27 (17.2) 29 (18.6)
Alpha fetoprotein
< 400 ng/mL 60 (47.6) 53 (42.1) 100 (63.7) 97 (62.2)
≥ 400 ng/mL 66 (52.4) 73 (57.9) 53 (33.8) 58 (37.2)
Missing 0 0 4 (2.5) 1 (0.6)
Data are n (%) unless otherwise indicated. aPerformance status evaluated according to guidelines of the Eastern Cooperative 
Oncology Group (ECOG), with a performance status (PS) of 0 indicating asymptomatic, 1 restricted in strenuous activity but 
ambulatory and able to do light work, or 2 ambulatory and capable of all self-care but unable to work. Abbreviations: BCLC 
= Barcelona Clinic Liver Cancer staging system; ECOG PS = Eastern Cooperative Oncology Group performance status.  
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Figure 1: Trial profile for East Asian and non-East Asian patients. 
Table 2: Best overall response










Complete response 0 0 1 (0.6) 0
Partial response 7 (5.6) 1 (0.8) 12 (7.6) 1 (0.6)
Stable disease 53 (42.1) 52 (41.3) 86 (54.8) 75 (48.1)
Progressive disease 57 (45.2) 62 (49.2) 40 (25.5) 67 (42.9)
Not evaluable or assessed 9 (7.1) 11 (8.7) 18 (11.5) 13 (8.3)
Objective response rate 7 (5.6) 1 (0.8) 13 (8.3) 1 (0.6)
95% CI 2.7–11.0 0.1–4.4 4.9–13.7 0.1–3.5
p-value 0.0298 0.0012
Disease control ratea 60 (47.6) 53 (42.1) 99 (63.1) 76 (48.7)
95% CI 39.1–56.3 33.8–50.8 55.3–70.2 41.0–56.5
p-value 0.3568 0.0096
Data are n (%) unless otherwise indicated. aDenotes best response for complete response, partial response, or stable disease. 
Abbreviation: CI = confidence interval.
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of patients and at a higher rate in the ramucirumab arm 
than the placebo arm were hypertension and malignant 
neoplasm progression for EA patients (Table 3; data 
not shown for malignant neoplasm progression), and 
hypertension, asthenia, ascites, general physical health 
deterioration, thrombocytopenia, and malignant neoplasm 
progression for non-EA patients (Table 4; data not shown 
for general physical health deterioration and malignant 
neoplasm progression). 
The incidences of adverse events of special interest 
(AESIs) are shown in Tables 3 and 4 for EA and non-EA 
patients, respectively. Any grade AESIs that were more 
common (at least 10% difference) in the ramucirumab arm 
than the placebo arm were liver injury/failure, bleeding/
hemorrhage, proteinuria, and hypertension for EA patients 
(Table 3), and liver injury/failure, hypertension, and 
proteinuria for non-EA patients (Table 4). Grade ≥ 3 AESIs 
that occurred at a higher rate in the ramucirumab arm than 
the placebo arm were hypertension, proteinuria, and renal 
failure for EA patients (Table 3), and hypertension, renal 
failure, infusion-related reaction, and proteinuria for non-
EA patients (Table 4). 






Any Grade Grade ≥ 3 Any Grade Grade ≥ 3
Treatment-emergent adverse events
Any 119 (96.7) 64 (52.0) 110 (89.4) 48 (39.0)
Peripheral edema 41 (33.3) 0 15 (12.2) 0
Fatigue 28 (22.8) 2 (1.6) 20 (16.3) 4 (3.3)
Decreased appetite 26 (21.1) 2 (1.6) 26 (21.1) 0
Diarrhea 26 (21.1) 0 7 (5.7) 0
Headache 25 (20.3) 1 (0.8) 3 (2.4) 0
Ascites 24 (19.5) 4 (3.3) 14 (11.4) 4 (3.3)
Thrombocytopenia 24 (19.5) 5 (4.1) 6 (4.9) 0
Proteinuria 23 (18.7) 4 (3.3) 11 (8.9) 0
Pyrexia 22 (17.9) 0 14 (11.4) 0
Hypertension 21 (17.1) 8 (6.5) 8 (6.5) 1 (0.8)
Hypoalbuminemia 19 (15.4) 2 (1.6) 6 (4.9) 0
AAT increase 18 (14.6) 8 (6.5) 20 (16.3) 15 (12.2)
Epistaxis 18 (14.6) 0 5 (4.1) 0
Adverse events of special interest
Liver injury/failurea 59 (48.0) 23 (18.7) 38 (30.9) 24 (19.5)
Bleeding/hemorrhagea 38 (30.9) 6 (4.9) 17 (13.8) 8 (6.5)
  Gastrointestinal hemorrhageb 10 (8.1) 4 (3.3) 7 (5.7) 5 (4.1)
  Pulmonary hemorrhageb 4 (3.3) 0 2 (1.6) 1 (0.8)
  Hepatic hemorrhageb 1 (0.8) 1 (0.8) 2 (1.6) 2 (1.6)
Proteinuriaa 24 (19.5) 4 (3.3) 11 (8.9) 0
Hypertensiona 22 (17.9) 9 (7.3) 8 (6.5) 1 (0.8)
Renal failurea 10 (8.1) 2 (1.6) 6 (4.9) 0
Infusion-related reactiona 4 (3.3) 0 1 (0.8) 0
Arterial thromboembolic eventsa 1 (0.8) 0 2 (1.6) 1 (0.8)
Venous thromboembolic eventsa 1 (0.8) 0 1 (0.8) 1 (0.8)
Data are n (%). Only treatment-emergent adverse events in ≥ 15% of patients in the ramucirumab arm in East Asian patients 
are reported. A patient was only counted once for each category. Missing grades are counted in ‘Any Grade’. Adverse 
events were coded using MedDRA version 16.1. aPooled adverse event terms. bPooled adverse event category comprising 
synonymous MedDRA preferred terms. Abbreviation: AAT = aspartate aminotransferase.
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DISCUSSION
This subgroup analysis of REACH indicates that, 
while no significant OS benefit was shown in EA patients, 
there were improvements in PFS and ORR. Similar 
findings were noted in non-EA patients. Patients with AFP 
≥400 ng/mL appeared to have a more favorable OS benefit 
in both the EA and non-EA groups, consistent with the 
findings in the overall intent-to-treat (ITT) population with 
AFP ≥ 400 ng/mL. 
Overall, the survival benefit of ramucirumab was 
comparable in EA patients and non-EA patients, although 
EA patients had a shorter median OS compared with 
non-EA patients. A shorter median OS for EA patients 
versus non-EA patients was also observed in the SHARP 
and Asia-Pacific studies of sorafenib in hepatocellular 






Any Grade Grade ≥ 3 Any Grade Grade ≥ 3
Treatment-emergent adverse events
Any 151 (98.1) 108 (70.1) 150 (98.0) 84 (54.9)
Peripheral edema 60 (39.0) 1 (0.6) 35 (22.9) 1 (0.7)
Ascites 50 (32.5) 9 (5.8) 26 (17.0) 7 (4.6)
Asthenia 48 (31.2) 13 (8.4) 33 (21.6) 4 (2.6)
Fatigue 36 (23.4) 4 (2.6) 38 (24.8) 4 (2.6)
Nausea 36 (23.4) 0 31 (20.3) 0
Decreased appetite 35 (22.7) 3 (1.9) 24 (15.7) 2 (1.3)
Hypertension 34 (22.1) 26 (16.9) 12 (7.8) 9 (5.9)
Abdominal pain 32 (20.8) 4 (2.6) 42 (27.5) 10 (6.5)
Headache 28 (18.2) 1 (0.6) 12 (7.8) 0
Cough 27 (17.5) 1 (0.6) 14 (9.2) 0
Diarrhea 25 (16.2) 3 (1.9) 31 (20.3) 1 (0.7)
Pyrexia 24 (15.6) 1 (0.6) 12 (7.8) 1 (0.7)
Thrombocytopenia 24 (15.6) 8 (5.2) 6 (3.9) 1 (0.7)
Constipation 23 (14.9) 0 26 (17.0) 0
Adverse events of special interest
Liver injury/failurea 81 (52.6) 35 (22.7) 65 (42.5) 41 (26.8)
Bleeding/hemorrhagea 52 (33.8) 11 (7.1) 38 (24.8) 13 (8.5)
  Gastrointestinal hemorrhageb 15 (9.7) 7 (4.5) 16 (10.5) 12 (7.8)
  Pulmonary hemorrhageb 5 (3.2) 1 (0.6) 2 (1.3) 1 (0.7)
  Hepatic hemorrhageb 1 (0.6) 1 (0.6) 0 0
Hypertensiona 34 (22.1) 26 (16.9) 12 (7.8) 9 (5.9)
Proteinuriaa 24 (15.6) 2 (1.3) 2 (1.3) 0
Infusion-related reactiona 16 (10.4) 3 (1.9) 1 (0.7) 0
Renal failurea 10 (6.5) 4 (2.6) 12 (7.8) 3 (2.0)
Venous thromboembolic eventsa 5 (3.3) 2 (1.3) 3 (2.0) 3 (2.0)
Arterial thromboembolic eventsa 1 (0.6) 0 2 (1.3) 0
Congestive heart failurea 0 0 2 (1.3) 1 (0.7)
Healing complicationa 0 0 1 (0.7) 0
Data are n (%). Only treatment-emergent adverse events in ≥ 15% of patients in the ramucirumab arm in non-East Asian 
patients are reported. A patient was only counted once for each category. Missing grades are counted in ‘Any Grade’. Adverse 
events were coded using MedDRA version 16.1. aPooled adverse event terms. bPooled adverse event category comprising 
synonymous MedDRA preferred terms. Abbreviation: AAT = aspartate aminotransferase.
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carcinoma [3, 4]. The shorter median OS for EA patients 
in REACH may partly be due to a higher prevalence of 
baseline characteristics associated with poor prognosis in 
EA patients compared to non-EA patients. For instance, 
EA patients in REACH had a higher incidence of hepatitis 
B infection, macrovascular invasion, extrahepatic 
spread, Barcelona Clinic Liver Cancer stage C, increased 
concentration of AFP, and poorer ECOG PS than non-EA 
patients. In addition, more EA patients were aged less 
than 65 years compared with non-EA patients. Notably, 
patients in the Asia-Pacific study were also reported to 
have a higher incidence of hepatitis B, extrahepatic spread, 
Barcelona Clinic Liver Cancer stage C, poorer ECOG PS, 
and younger age compared to patients enrolled in the 
SHARP study [3,4]. Post-discontinuation systemic anti-
cancer therapy in REACH is unlikely to have contributed 
to the shorter OS in EA patients compared with non-EA 
patients given that a higher percentage of EA patients 
(38%) received PDT compared with non-EA patients 
(24%). Furthermore, no treatment has demonstrated a 
survival benefit to date in hepatocellular carcinoma after 
sorafenib treatment [15–18]. The improvement in PFS in 
EA patients was consistent with the improvement in non-
EA patients, although PFS was shorter and the DCR was 
lower for EA patients than non-EA patients. The shorter 
PFS and DCR for EA patients may reflect the poorer 
prognosis and more rapidly progressive disease in the 
EA population. Despite known regional differences in 
the etiology and prognosis of hepatocellular carcinoma, 
ramucirumab demonstrated comparable survival efficacy 
in both EA and non-EA patients. These efficacy findings 
were similar to the overall REACH ITT population [15]. 
In patients with a baseline AFP ≥ 400 ng/mL, an 
improvement in OS was observed in both EA and non-EA 
patients treated with ramucirumab compared to placebo. 
This did not reach significance in the EA subgroup, likely 
due to the limitations of small sample size. Nonetheless, 
the difference in median OS was similar in the EA and 
non-EA subgroups and is generally consistent with the 
survival benefit observed in the overall ITT population 
with a baseline AFP ≥ 400 ng/mL in REACH [15]. This 
benefit was observed despite the overall poorer prognosis 
associated with EA patients compared to non-EA patients. 
We note that in the patients with baseline AFP ≥400 ng/mL, 
both EA and non-EA patients share a similar median 
OS in the placebo arm, which suggests that selection of 
Figure 2: Kaplan-Meier plots of overall survival (A and B) and progression-free survival (C and D) for East Asian 
(A and C) and non-East Asian patients (B and D).
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this subset of patients may normalize any differences in 
prognosis between regions. Consistent with the overall 
ITT population with baseline AFP < 400 ng/mL [15], 
no OS benefit was observed in EA or non-EA patients 
with ramucirumab treatment. The OS results from these 
subgroup analyses demonstrate that a baseline AFP 
≥ 400 ng/mL may identify patients who are most likely 
to benefit from ramucirumab treatment, regardless of 
whether they are from EA or non-EA regions.
The efficacy benefits for EA and non-EA patients 
were achieved with an acceptable safety profile. The 
majority of AESIs were grade 1–2, and the grade ≥ 3 
AESIs were generally comparable between EA and non-
EA patients. The observed safety profiles for EA and 
non-EA patients were consistent with the underlying 
disease state and the overall ITT populations in trials of 
ramucirumab [15, 19, 20]. Liver injury and bleeding are of 
particular concern in patients with advanced hepatocellular 
carcinoma, who often have underlying cirrhosis. In both 
EA and non-EA patients, increases in the low grade 
AESIs of liver injury/failure and bleeding/hemorrhage 
were observed in the ramucirumab arms compared with 
the placebo arms, but an increase in higher grade events 
was not observed. Notably, no increased rate of high grade 
AESIs was observed in EA patients compared to non-
EA patients, despite the prevalence of poor prognostic 
characteristics in the EA subgroup that might have put 
these patients at higher risk with ramucirumab treatment.
This subgroup analysis has a number of limitations 
including the fact that the study was not designed or 
powered to show significance in the EA and non-EA 
subgroups, which makes it difficult to make accurate 
inferences. Furthermore, this analysis was post-hoc and 
caution should be used when interpreting the results. 
Despite these limitations, the efficacy observations in the 
subgroups defined by an AFP < or ≥ 400 ng/mL have been 
very consistent, and therefore seem unlikely to be due to 
chance.
In this subgroup analysis of the REACH trial, 
ramucirumab generally demonstrated consistent efficacy 
across EA and non-EA regions. The data indicate that 
patients with baseline AFP ≥ 400 ng/mL may be deriving 
the majority of the benefit observed in both EA and 
non-EA patients. Ramucirumab was well tolerated in 
both EA and non-EA patients. Further evaluation of 
ramucirumab in patients with advanced hepatocellular 
Figure 3: Kaplan-Meier plots of overall survival in patients with baseline alpha-fetoprotein ≥ 400 ng/mL (A and B) and 
alpha-fetoprotein < 400 ng/mL (C and D) for East Asian (A and C) and non-East Asian patients (B and D).
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carcinoma is warranted. The REACH-2 trial will evaluate 
the efficacy and safety of ramucirumab in a global 
cohort of participants with hepatocellular carcinoma 
and elevated baseline AFP (ClinicalTrials.gov Identifier: 
NCT02435433).
MATERIALS AND METHODS
Study design and patients
The study design and demographic information for 
patients in REACH have been published previously [15]. 
Each center’s institutional review board or independent 
ethics committee approved this study. The study followed 
the guiding principles of the Declaration of Helsinki and 
the Good Clinical Practice Guidelines of the International 
Conference on Harmonization. All patients provided 
written informed consent before enrollment. This study is 
registered with ClinicalTrials.gov, number NCT01140347.
Randomization and procedures
Randomization and procedures have been published 
previously [15]. Patients were randomly assigned in a 1:1 
ratio to receive either ramucirumab 8 mg/kg or placebo 
intravenously every two weeks until disease progression, 
unacceptable toxicity, or withdrawal of consent. All 
patients received best supportive care. Predefined dose 
modifications were allowed to manage treatment-related 
toxicity. Randomization was stratified by geographic 
region (region 1 [n = 65]: Brazil, Canada, and the United 
States vs. region 2 [n = 248]: Australia, Europe, and Israel 
vs. region 3 [n = 252]: East Asia) and etiology of liver 
disease (hepatitis B vs. hepatitis C vs. other etiologies). 
Region 1 consisted of Brazil (n = 27), Canada (n = 1), and 
the United States (n = 37); region 2 consisted of Australia 
(n = 11), Austria (n = 8), Belgium (n = 8), Bulgaria 
(n = 6), the Czech Republic (n = 20), Finland (n = 3), 
France  (n = 59), Germany (n = 40), Hungary (n = 1), 
Israel (n = 2),  Italy (n = 51), the Netherlands (n = 3), 
Norway (n = 2), Portugal (n = 2), Romania (n = 7), Spain 
(n = 21), Sweden (n = 2), and Switzerland (n = 2); and 
region 3 consisted of Hong Kong (n = 24), Japan (n = 93), 
Philippines (n = 1), South Korea (n = 70), Taiwan 
(n = 58), and Thailand (n = 6). 
Statistical analysis
Statistical methodology was the same as published 
previously [15]. The EA and non-EA subgroups were 
separately analyzed. The EA patient population was 
defined and analyzed as patients enrolled at study sites 
in region 3. The non-EA patient population was defined 
and analyzed as patients enrolled at study sites in regions 
1 and 2 combined. 
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